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Introduction
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common
malignancy in children and involves uncontrolled expansion of B-lymphoid progen-
itors in the bone marrow. The disease is frequently initiated by a chromosomal
translocation but becomes manifest only when leukemic progenitors in the bone
marrow have accumulated a number of additional gene deletions and mutations
that drive disease progression. With current treatment protocols long-term survival
approaches 90%;1 however, relapses still pose a significant clinical challenge due to
resistance to chemotherapy of the recurrent disease.1 Both in pediatric and adult
BCP-ALL, specific genetic subtypes with distinct prognostic outcomes can be iden-
tified2 Some of these subtypes, such as hyperdiploid ALL and ETV6-RUNX1-
rearranged ALL are associated with a favorable outcome, while other genetic hall-
marks, such as MLL gene rearrangements, hypodiploidy, intrachromosomal
translocation of chromosome 21 (iAMP21), or the presence of the t(9;22) BCR-ABL1
translocation predict poor outcome. Moreover, the presence of a gene expression
profile similar to that of BCR-ABL1-positive ALL, which frequently involves genetic
alterations that deregulate cytokine receptor and/or  tyrosine kinase signaling, is
similarly associated with poor outcome.2 In addition to these gross chromosomal
rearrangements, deletions or mutations affecting the B-cell transcription factor
IKZF1, are a strong and independent predictor of poor outcome in BCP-ALL.3,4
Together with its role as a critical regulator of B-cell development and a leukemia
tumor suppressor, there is mounting evidence that IKZF1 loss also affects signaling
pathways that modulate therapy response.  
Here, we provide an overview of the complex role of transcription factor IKZF1
during normal lymphopoiesis and consequences of IKZF1 loss for the pathogenesis
of BCP-ALL. Finally, we discuss some of the molecular mechanisms by which
IKZF1 gene alterations may contribute to therapy resistance. 
Transcription regulation by IKAROS zinc-finger protein 1
The IKAROS family of transcription factors consists of five different IKAROS
zinc-finger proteins (IKZF1-IKZF5) that are able to bind DNA directly at the core
Transcription factor IKZF1 (IKAROS) acts as a critical regulator oflymphoid differentiation and is frequently deleted or mutated in B-cell precursor acute lymphoblastic leukemia. IKZF1 gene defects
are associated with inferior treatment outcome in both childhood and
adult B-cell precursor acute lymphoblastic leukemia and occur in more
than 70% of BCR-ABL1-positive and BCR-ABL1-like cases of acute lym-
phoblastic leukemia. Over the past few years, much has been learned
about the tumor suppressive function of IKZF1 during leukemia develop-
ment and the molecular pathways that relate to its impact on treatment
outcome. In this review, we provide a concise overview on the role of
IKZF1 during normal lymphopoiesis and the pathways that contribute to
leukemia pathogenesis as a consequence of altered IKZF1 function.
Furthermore, we discuss different mechanisms by which IKZF1 alter-
ations impose therapy resistance on leukemic cells, including enhanced
cell adhesion and modulation of glucocorticoid response.
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ABSTRACT
motif A/GGGAA through their N-terminal zinc-finger
domain.5,6 Furthermore, all IKAROS family members har-
bor two additional C-terminal zinc-fingers required for
homo- and heterodimerization between the different
IKZF proteins (Figure 1A). The formation of homo- or het-
erodimers between IKAROS zinc-finger proteins with a
functional DNA binding domain strongly enhances their
DNA affinity and transcriptional activity. However, a
common feature of IKZF1 and related family members is
the presence of shorter variants due to alternative splicing.
These variants often lack DNA binding activity but retain
the ability to interact with full-length IKZF1-IKZF5, there-
by creating dominant-negative isoforms. A well-known
splice variant of both the mouse and human IKZF1 gene is
the IK6 isoform, which lacks exons 4 to 7 that encode the
four N-terminal zinc-fingers representing the DNA bind-
ing domain (Figure 1B).   
IKZF1 mainly regulates gene expression through associ-
ation with the nucleosome remodeling and deacetylase
complex,7-10 which includes histone deacetylases HDAC1,
HDAC2 and the ATP-dependent chromatin remodeling
proteins CHD3 and CHD4. The nucleosome remodeling
and deacetylase complex is involved in both transcription-
al repression as well as gene activation by IKZF1.11,12 Gene
silencing by IKZF1 is also facilitated through interaction
with Polycomb repressive complex 2, which promotes
histone H3 lysine 27 trimethylation to maintain genes in
an inactive state.13,14 Other transcriptional co-factors that
can associate with IKZF1 and mediate gene regulation
include CtBP, CtIP and SWI/SNF-related complex.15-17 On
the other hand, IKZF1 may itself participate in transcrip-
tion initiation through direct interactions with the general
transcription factors TFIIB and TBP.16 IKZF1 also controls
transcription elongation via association with protein phos-
phatase 1α and cyclin-dependent kinase 9 (CDK9), the
enzymatic component of the positive transcription elon-
gation factor b.18-20 IKZF1-mediated transfer of protein
phosphatase 1α to CDK9 promotes activation of positive
transcription elongation factor b and recruitment to gene
regulatory regions, thereby facilitating transcription elon-
gation of IKZF1-target genes in hematopoietic cells.18 
Distinct post-translational modifications are able to
modify the function of IKZF1. Phosphorylation of IKZF1
at multiple serine and threonine residues by casein kinase
II impairs its function as a transcription factor.20-22
Conversely, casein kinase II inhibition enhances the tran-
scriptional repressor function of IKZF1.23 On the other
hand, dual-specificity kinases BTK and SYK both phos-
phorylate IKZF1 on specific serine residues in close prox-
imity of the DNA binding domain to augment its nuclear
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Figure 1. Overview of the human family of
IKAROS zinc-finger (IKZF) transcription factors
and IKZF1 isoforms. (A) Schematic representa-
tion of the five IKZF proteins (IKZF1-IKZF5),
including the N-terminal zinc-fingers that define
the DNA-binding domain and the two C-terminal
zinc-fingers representing the dimerization
domain. The colored boxes indicate the individ-
ual regions within the protein that are encoded
by distinct exons. (B) The common IKZF1 splice
variants (IK1-IK8) are shown, including the short-
er isoforms that are generated by alternative
splicing. The splice variants lacking exons 4 and
5 (IK6-IK8) represent dominant-negative iso-
forms of IKZF1.
A
B
localization and DNA binding activity.24,25 Sumoylation of
IKZF1 on lysine residues occurs within the nucleus and
seems to interfere with transcriptional repression.26,27 It
was previously shown that IKZF1 is also subject to ubiq-
uitination,20 and there is now renewed interest in this
pathway, since both IKZF1 and IKZF3 are targets of the
immunomodulatory drugs thalidomide, lenalidomide,
pomalidomide and CC-122.28 These immunomodulatory
drugs promote proteosomal degradation of IKZF1 and
IKZF3 by redirecting the substrate specificity of the
CRL4CRBN ubiquitin ligase complex.29,30 Immunomodulatory
drugs show therapeutic effects in a broad range of hema-
tologic malignancies through their ability to target the
malignant cells and modulate the immune system and its
microenvironment.
IKZF1 is essential for normal lymphopoiesis
Studies performed in both constitutive and conditional
Ikzf1 knockout mouse models have demonstrated that
IKZF1 function is not only required at different stages of
lymphopoiesis,12,31,32 but also for normal myeloid,
megakaryocyte and erythroid differentiation.33-36 Ikzf1-
deficient mice (Ikzf1null/null) lack all B cells, natural killer cells,
plasmacytoid dendritic cells and fetal T cells31,37 (Figure 2).
Nonetheless, post-natal Ikzf1-null mice harbor early T lin-
eage progenitors within the thymus and export mature T
cells to the periphery.38 Mice homozygous mutant for a
hypomorphic allele of Ikzf1 (Ikzf1L/L) show reduced B-cell
progenitors in the bone marrow compartment, but still
generate normal counts of mature B2 cells.39 These splenic
B cells display alterations in isotype selection during
immunoglobulin class switch recombination and a hyper-
proliferation phenotype upon antigenic stimulation.40,41
Although spontaneous progression to B-cell ALL is not
observed in Ikzf1L/L mice, haplodeficient Ikzf1L/+ animals
demonstrate an accelerated onset of B-cell leukemia in
combination with a BCR-ABL1 transgene.42 Moreover, all
Ikzf1L/L mice develop thymic lymphoma within a period of
10 months through activation of the Notch pathway.43
Ikzf1mutant mice expressing dominant-negative isoforms
of IKZF1 (Ikzf1DN/DN and Ikzf1Plstc/Plstc) demonstrate a wide-
spread failure of hematopoiesis,44,45 highlighting the impor-
tance of IKAROS transcription factors in hemato-lym-
phoid differentiation. Notably, heterozygous Ikzf1mutant
mice develop T-cell malignancies with very high pene-
trance and short latency in the case of the dominant-neg-
ative isoforms,46,47 while this phenotype is less obvious in
Ikzf1+/- mice.48
Detailed gene expression profiling has revealed that
IKZF1 is essential for the generation of common lymphoid
progenitors by priming lymphoid lineage-specific signa-
tures in hematopoietic stem cells and lymphoid-primed
IKZF1 in leukemia and therapy response
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Figure 2. Summary of the observed phenotypes in the different constitutive Ikzf1 knockout mouse models. The knockout allele shows a schematic representation
at which position the deletion or mutation is present in the mouse Ikzf1 gene. DN: dominant negative; Plstc: ENU-induced dominant-negative point mutation, called
Plastic; Neo: neomycin gene; βGeo: fusion between LacZ and neomycin gene; ZF: zinc-finger; HSC: hematopoietic stem cell; NK: natural killer; pDCs: plasmacytoid
dendritic cells; LT-HSC: long-term hematopoietic stem cell; GMPs: granulocyte-macrophage precursors; mo: months.
multipotent progenitors.49 At different stages of T-lineage
differentiation and development, IKZF1 is engaged by set-
ting thresholds for (pre-)T-cell receptor-controlled check-
points as well as T-cell activation downstream of inter-
leukin-2 receptor signaling.50,51 In B-cell progenitors, Ikzf1
is required to induce Rag1 and Rag2 expression, and medi-
ates chromatin accessibility during immunoglobulin gene
rearrangement and allelic exclusion at the Igk locus.12,32,52
During pre-B-cell differentiation, IKZF1 regulates the tran-
scription of genes implicated in pre-B-cell receptor signal-
ing, cell survival, stromal-cell adhesion and B-cell commit-
ment, such as Pax5, Foxo1 and Ebf1.12,32,53 Many of those
regulatory activities during B-lineage differentiation are
navigated by super-enhancer networks controlled by
IKZF1 and other B-cell master transcription factors.54
Besides regulating expression of B-lymphoid genes, IKZF1
is actively involved in repression of a lineage-inappropri-
ate transcriptional program normally prevalent in epithe-
lial and mesenchymal precursors.54
To further delineate the function of the individual zinc-
fingers within the DNA-binding domain of IKZF1 in B-
lymphopoiesis, Ikzf1 mouse mutants have been generated
with targeted deletion of exon 4, which encodes zinc-fin-
ger 1 (Ikzf1ΔF1/ΔF1), or exon 6 encoding zinc-finger 4
(Ikzf1ΔF4/ΔF4).37 Germline deletion of either exon 4 or 6 results
in decreased B-cell precursors with a stronger developmen-
tal block in Ikzf1ΔF1/ΔF1 mice, especially at the pre-B-cell
stage.37 In contrast, the fraction of large pre-B cells is strong-
ly increased in Ikzf1ΔF4/ΔF4 mice as compared to wild-type
control animals. Interestingly, deletion of zinc-finger 4, but
not zinc-finger 1, accelerates the onset of BCR-ABL1-medi-
ated B-cell leukemia.37,55 Conditional deletion of exon 5
(Ikzf1E5Δ/Δ), which encodes zinc-fingers 2 and 3, at the stage
of common lymphoid progenitors also results in an expan-
sion of large pre-B cells within the bone marrow compart-
ment, which is followed by a subsequent block in the tran-
sition to small pre-B cells.56 These findings indicate that N-
terminal zinc-fingers 2, 3 and 4 of IKZF1 limit cell prolifer-
ation and survival at the time of active pre-B-cell receptor
signaling, while zinc-fingers 1, 2 and 3 are absolutely
required for the transition to the pre-B-cell stage. 
IKZF1 gene lesions drive leukemia development 
and relapse
In the past decade, complementary genome-wide
approaches have been employed to identify the genetic
drivers implicated in the pathogenesis of ALL. Those stud-
ies revealed that the IKZF1 gene, which is located on chro-
mosome band 7p12.2, is recurrently affected by different
types of genetic alterations in BCP-ALL. Analysis of copy
number alterations has demonstrated that IKZF1 gene
deletions are present in about 15% of cases of childhood
BCP-ALL and 40%-50% of adult patients with BCP-
ALL.57-60 These deletions frequently involve the whole
gene (DEL1-8) that results in loss of expression of wild-
type IKZF1, as well as focal deletions that alter the func-
tion of IKZF1, such as the dominant-negative isoform IK6
(DEL4-7). Other common variants include deletions
affecting exons 2-3, exons 2-7 and exons 4-8.61 In most
cases these are monoallelic IKZF1 deletions where one
functional copy of IKZF1 is retained, although biallelic
deletions are also observed in a fraction of BCP-ALL
cases.62,63 In addition, IKZF1 function is compromised by
insertions, frameshift and missense mutations, which rep-
resent ~7% of IKZF1 alterations in BCP-ALL.63
Furthermore, rare in-frame gene fusions involving IKZF1
have been identified by RNA sequencing in BCP-ALL,
including IKZF1-NUTM1, IKZF1-SETD5 and the recipro-
cal SETD5-IKZF1.64 However, it remains to be established
whether these IKZF1 gene fusions are pathogenic and
contribute to leukemia development.   
An interesting feature is the strongly increased preva-
lence of IKZF1 deletions and mutations in high-risk BCP-
ALL cases with an activated tyrosine kinase profile, partic-
ularly BCR-ABL1-positive  ALL (~85%),65 and BCR-ABL1-
like ALL (~70%), which is characterized by a range of
genetic alterations driving cytokine receptor and kinase
signaling.3,66-68 Similarly, IKZF1 deletions and mutations are
highly abundant in chronic myeloid leukemia that has
progressed to lymphoid blast crises, but IKZF1 alterations
are virtually absent in chronic-phase and myeloid blast cri-
sis chronic myeloid leukemia.65,69,70 IKZF1 deletions are
also rarely detected in ETV6-RUNX1-positive BCP-ALL
(3%), TCF3-rearranged (~3%) and MLL-rearranged (~5%)
B-cell ALL.58,71,72 The distribution of IKZF1 deletions among
the remaining subtypes, including hyperdiploid and B-
other leukemia, ranges from 15%-20%.72
IKZF1 acts as a critical tumor suppressor in mouse T-
lymphoid malignancies,43,46,47 but  IKZF1 gene lesions are
not very prevalent in T-ALL. Copy number alterations and
mutations affecting the IKZF1 gene can be detected in
~4% of T-ALL.58,65,71,73 Notably, IKZF1 alterations occur in
~13% of early T-cell precursor ALL, a high-risk subtype of
T-ALL characterized by recurrent mutations activating
tyrosine kinases (FLT3, JAK1, JAK3) and cytokine signaling
(IL7R).74 IKZF1 alterations have also been reported in
myeloproliferative neoplasms,75 and both pediatric and
adult acute myeloid leukemia harbor IKZF1 deletions that
affect its function.76,77 Thus, the tumor suppressive activity
of IKZF1 is not uniquely restricted towards the lymphoid
lineage and extends to a broader range of hematologic
malignancies.
Besides its critical role in the pathogenesis of leukemia,
IKZF1 alterations are also associated with adverse progno-
sis in BCP-ALL.3,4,78 even within the high-risk group of
BCR-ABL1-positive ALL.79,80 Notably, the occurrence and
prognostic impact of IKZF1 alterations is not restricted to
high-risk cases, but is also observed in standard-risk B-ALL
subtypes,72 including high hyperploidy.81 Indeed, IKZF1
deletion represents one of the strongest independent pre-
dictors of poor treatment outcome in childhood BCP-
ALL.71,72,82 Similar data have been reported in adult BCP-
ALL, where loss-of-function gene deletions of IKZF1 pre-
dict poor treatment outcome in BCR-ABL1-negative
cases.83-86 Interestingly, the presence of other co-occurring
gene lesions may either enhance or negate the prognostic
value of IKZF1 deletions. For instance, focal deletions
affecting both transcriptional regulator BTG1 and IKZF1
represent a high-risk group with a worse outcome than
those with IKZF1 alterations alone.48 On the other hand,
the BCP-ALL subtype characterized by deregulation of
transcription factors ERG and DUX4 has a favorable out-
come, despite the presence of IKZF1 deletions in approxi-
mately 40% of these patients.64,87-90 An explanation for this
latter observation remains elusive. 
Genetic alterations that cooperate with IKZF1
deletions in B-cell precursor acute lymphoblastic leukemia
There is accumulating evidence that recurrent chromo-
somal aberrations present in BCP-ALL, such as BCR-ABL1
R. Marke et al.
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translocations or CRLF2 rearrangements, act as driver
lesions and represent early events in leukemia develop-
ment. Genome-wide analysis has established that several
other genetic alterations cooperate before B-cell leukemia
becomes manifest. Gene lesions that inactivate the lym-
phoid transcription factor IKZF1 are frequently observed
in BCR-ABL1-positive and CRLF2-rearranged BCP-
ALL.65,69,91,92 The latter group is associated with concomi-
tant JAK1 and JAK2 activating mutations.91 Similarly,
IKZF1 alterations are highly prevalent in tyrosine kinase-
activating lesions that define BCR-ABL1-like ALL.67,68
These include rearrangements involving ABL1/ABL2,
CSF1R, EPOR, JAK2 and PDGFRB, or sequence mutations
affecting FLT3, IL7R or SH2B3. Indeed, loss of IKZF1 may
permit more effective STAT5 target gene regulation down-
stream of these pathways.93 Collectively, these findings
argue that loss of IKZF1 function strongly cooperates with
activated tyrosine kinase signaling pathways linked to
enhanced progenitor B-cell proliferation and immortaliza-
tion (Figure 3). 
The predilection for IKZF1 gene alterations in BCR-
ABL1-mediated lymphoid versusmyeloid malignancies has
been further corroborated in mouse studies. In a bone
marrow transplantation model using lineage-negative
hematopoietic progenitor cells, it was shown that expres-
sion of IK6 skews BCR-ABL1-mediated leukemia from an
exclusive myeloproliferative disease towards a combined
myeloid and B-lymphoid disease.63 Introducing p19Arf-defi-
ciency further strengthens this trend towards uniformly
induced B-cell ALL. This is in agreement with the finding
that BCR-ABL1-positive BCP-ALL is characterized by the
co-occurrence of IKZF1 and CDKN2A gene deletions.65
Another group of genetic changes that frequently co-
occur with IKZF1 alterations in BCP-ALL include gene
deletions affecting lymphoid transcription factors, such as
EBF1 and PAX5, and the transcriptional co-factor BTG148,58
(Figure 3). BTG1 belongs to the BTG/TOB antiprolifera-
tive (APRO) family of proteins,94 which control gene tran-
scription by their ability to interact with specific transcrip-
tion factors, such as nuclear receptors and homeobox pro-
teins.95,96 the CCR4-NOT transcriptional regulatory com-
plex,97 or through recruitment of protein arginine methyl
transferase PRMT1.98 In addition, BTG1 through interac-
tion with the CCR4-NOT, may also regulate mRNA dead-
enylation and consequently mRNA decay.99,100 Mice defi-
cient for Btg1 show a partial block in B-cell development,
IKZF1 in leukemia and therapy response
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Figure 3. Pathways cooperating with IKZF1 alterations in leukemia pathogenesis. Pathways involving cytokine receptor signaling and B-cell differentiation by lym-
phoid transcriptional regulators in normal progenitor B cells are schematically indicated on the left. Alterations of these pathways co-occur frequently with IKZF1
deletions and mutations in B-cell progenitor acute lymphoblastic leukemia (BCP-ALL) as indicated on the right. These include, activating mutations in FLT3, IL7R,
JAK2 (*), upregulation of CRLF2 (+), C-terminal truncations or upregulation of EPOR (^), chromosomal translocations generating fusion proteins with PDGFR or CSF1R
(-), and BCR-ABL1, which collectively results in activated cytokine receptor and tyrosine kinase signaling leading to STAT activation. In addition, IKZF1 alterations co-
occur with gene deletions affecting the activity of B-lymphoid transcriptional regulators EBF1, PAX5 and BTG1, which results in a block of B-cell differentiation. FLT3:
FMS related tyrosine kinase 3; IL7R: interleukin 7 receptor; CRLF2: cytokine receptor like factor 2; C-KIT: mast/stem cell growth factor receptor Kit; JAK, Janus kinase;
STAT: signal transducer and activator of transcription; BTG1: B-cell translocation gene 1; EBF1: early B-cell factor 1; PAX5: paired box 5; IKZF1: IKAROS family zinc
finger 1; CSF1R: colony-stimulating factor 1 receptor;  EPOR: erythropoietin receptor; PDGFR: platelet-derived growth factor receptor.
which is even more evident in Btg1-/-;Btg2-/- mice.101 These
studies have demonstrated that BTG1, together with
BTG2, is required to suppress a T-lineage inappropriate
expression program in progenitor B cells. Thus, mono-
allelic gene deletions of IKZF1 in combination with EBF1,
PAX5 or BTG1may contribute to a more prominent block
in B-cell development and increased proliferative expan-
sion of precursor B cells. Indeed, intercrossing haplodefi-
cient Ikzf1 animals with heterozygous Ebf1 or Pax5 knock-
out mice promotes the onset of ALL, giving rise to both B-
ALL and T-ALL.102 On the other hand, Btg1-deficiency
specifically accelerates the development of T-ALL in
Ikzf1+/- mice, which suggests that B-lineage-restricted
mouse models will be required to establish their synergis-
tic action in the pathogenesis of B-ALL.
Effector pathways downstream of IKZF1 involved 
in leukemia pathogenesis
Since lymphoid transcription factors are commonly
deleted in BCP-ALL, the tumor suppressive functions of
IKZF1 and other B-cell master regulators, such as EBF1 and
PAX5, have been mostly linked to the suppression of their
B-cell differentiation programs in these leukemic cells.
However, this would not fully explain the predilection of
IKZF1 alterations in BCR-ABL1-positive and BCR-ABL1-
like leukemia, suggesting that IKZF1 also regulates other
molecular pathways. Furthermore, loss of IKZF1 function
probably affects different target genes in human leukemic
cells as compared to mouse progenitor B cells, which
could even be distinct from those deregulated by expres-
sion of dominant-negative isoforms, such as IK6.
Nonetheless, mouse studies performed over the past 5
years have been very instrumental in deciphering the tran-
scriptional networks downstream of IKZF1. Thus, gene
expression profiling in different Ikzf1 knockout mouse
models combined with genome-wide chromatin immuno-
precipitation studies has uncovered IKZF1-specific targets
that are not only linked to lymphoid lineage commitment
and B-cell differentiation, but also to leukemia develop-
ment. 
A large group of those Ikzf1-target genes can be classi-
fied as signal transducers, some of which drive early lym-
phoid differentiation, such as c-Kit, Flt3 and Il7r.12,32,37,53
Adult ALL samples harboring IKZF1 deletions display
increased expression of IL7R together with reduced
expression of SH2B3, which represents a defined subset of
high-risk B-ALL.103 Other genes differentially expressed in
Ikzf1-mutant mice are important for pre-B-cell receptor
signaling, and several of these IKZF1 targets appear to be
deregulated in BCR-ABL1-positive B-ALL, including
IGLL1, SYK, and SLP65.104,105 Indeed, defective pre-B-cell
receptor function is a hallmark of BCR-ABL1-positive ALL,
and loss of IKZF1 function enhances SRC phosphorylation
at the expense of the SYK/SLP65 pathway activation,
which is required for pre-B-cell differentiation.104 Besides
transcriptional regulation of signal transducers, Ikzf1 con-
trols the expression of cell surface receptors, such as CD34
and CD43, and these molecules confer a leukemic growth
advantage to IKZF1-mutated BCR-ABL1-positive B-ALL
cells.55 
Another group of IKZF1 target genes identified in
mouse progenitor B cells seems to converge on a cellular
network coupling cell surface protein expression with
intracellular Wnt and Rho signaling as well as catenin-dri-
ven gene regulation inside the nucleus.55,106 A critical target
gene within this subgroup includes Ctnnd1 encoding p120-
catenin. This is a multifunctional protein that regulates
cadherin stability at the cell membrane, activation of the
Rho family of GTPases in the cytoplasm and Wnt/β-
catenin target genes within the nucleus by interacting
with Kaiso.107 Activation of CTNND1 expression is
observed in samples from patients with IKZF1 deletions,108
and inactivation of p120-catenin reduces the proliferative
capacity of BCR-ABL1-positive leukemic cells.55,106 A relat-
ed downstream effector pathway of IKZF1 that plays an
eminent role during mouse B-cell development is integrin-
dependent survival signaling, which involves activation of
focal adhesion kinase (FAK).12,56 In mouse models of BCR-
ABL1-positive B-ALL, perturbation of Ikzf1, including loss-
of-function deletions and expression of IK6, leads to acti-
vation of an adhesive phenotype, which correlates with
overexpression of FAK.63,109 FAK pathway upregulation is
also observed in BCR-ABL1-positive BCP-ALL, especially
in the context of IK6 expression.109 Moreover, FAK inhibi-
tion potentiates the responsiveness to the ABL inhibitor
dasatinib in a xenograft model system and improves sur-
vival.109
Recently, it has been proposed that the B-lymphoid
transcriptional program regulated by IKZF1, as well as
PAX5, acts as a metabolic barrier against malignant trans-
formation of B-cell precursor cells.110 Inducible reconstitu-
tion of functional IKZF1 in patient-derived IKZF1-deleted
B-ALL cells results in activation of the LKB1-AMPK ener-
gy-stress-sensor pathway, and decreased protein levels of
the insulin receptor, the glucose transporters GLUT1,
GLUT3 and GLUT6, as well as the effectors of glucose
metabolism, such as HK2, HK3, and G6PD. On the other
hand, the expression of glucose-transport inhibitors, such
as TXNIP and CNR2, are strongly induced by IKZF1.
Consequently, these IKZF1-reconstituted B-ALL cells tran-
sit into a state of chronic energy deficit. Thus, this ‘meta-
bolic gatekeeper’ function of IKZF1 may force silent pre-
leukemic clones that carry potentially oncogenic lesions to
remain in a latent state.     
Besides imposing a change on pre-B-cell receptor signal-
ing, cell adhesion and metabolic state, IKZF1 alterations in
combination with BCR-ABL1 expression also result in
acquisition of stem cell-like features and enhanced self-
renewal of progenitor B cells63,105 (Figure 4). Activation of
THY1 expression has been linked to enhanced self-renew-
al,63 and Ikzf1 has been shown to regulate expression of
multiple genes involved in cell cycle regulation, including
Cdkn1a, Cdkn2a,  and Cdk6.53,55 In mouse progenitor B cells
and human B-ALL, BCL6 and MYC have been identified
as IKZF1 targets,32,111-113 and probably both contribute to
enhanced cell proliferation of IKZF1-deleted B-ALL.
However, it remains to be established whether targeting
these pathways has therapeutic potential in high-risk B-
ALL patients.
IKZF1 alterations mediate therapy resistance  
The presence of IKZF1 gene lesions in BCR-ABL1-posi-
tive B-ALL results in inferior treatment outcome and mouse
xenograft models suggest that IKZF1 loss contributes to
resistance to tyrosine kinase inhibitor-based therapy.63,80
Reactivation of cell adhesion pathways by perturbation of
IKZF1 function leads to elevation of key adhesion mole-
cules, such as integrins (ITGA5) and CD90, and adhesion
regulators, such as FAK, as well as increased phosphoryla-
tion of FAK itself, which permits relocalization of leukemic
R. Marke et al.
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cells to the bone marrow niche. Indeed, FAK inhibition re-
sensitizes BCR-ABL1 leukemic cells to tyrosine kinase
inhibitor therapy.109 Similar results are observed after treat-
ment with retinoids, specifically retinoid X receptor ago-
nists, which induce expression of wild-type IKZF1, but not
IK6, thereby abrogating expression of stem cell and adhe-
sion molecules.63 Although these studies have provided
important clues about how IKZF1 deletions alter treatment
response especially in the context of BCR-ABL1-positive
ALL, alternative mechanisms of therapy resistance may
exist besides protection through cell interactions within the
bone marrow microenvironment.
Synthetic glucocorticoids, such as prednisolone, consti-
tute essential drugs in the treatment of ALL patients and
glucocorticoid resistance remains a substantial problem in
the treatment of BCP-ALL. There is accumulating evi-
dence that IKZF1 deletions mediate prednisolone resist-
ance in vivo,114,115 but different mechanisms have been pro-
posed. IKZF1 actively represses genes of the phos-
phatidylinositol-3 kinase pathway, including PIK3CD and
PIK3C2B.23 Disruption of IKZF1 function, and subsequent
activation of the PI3K/AKT/mTOR pathway can promote
glucocorticoid resistance.116,117 IKZF1 controls expression of
several genes involved in glucose and energy supply.110
This metabolic program may alter the threshold for
responses to glucocorticoids in BCP-ALL. Specifically, the
glucocorticoid receptor NR3C1was reported to be a target
of IKZF1 in pre-B ALL cells, and downregulation of
NR3C1 protein levels could be observed upon expression
of IK6.110 However, studies performed in murine Ikzf1+/- B
cells and human BCP-ALL cell lines with short hairpin-
mediated IKZF1 knockdown have demonstrated that loss
of IKZF1 function induces glucocorticoid resistance inde-
pendently of altered NR3C1 mRNA and protein expres-
sion.114 Indeed, IKZF1 itself appears to regulate NR3C1-
dependent gene transcription.114 The transcriptional regu-
lator BTG1 has been identified as a modifier of IKZF1-
mediated resistance to glucocorticoid therapy and the
combined loss of BTG1 and IKZF1 leads to an even
stronger inhibition of glucocorticoid-induced cell death.48
Finally, IKZF1 target gene EMP1,106 which itself represents
a poor prognostic factor in pediatric ALL, was shown to
regulate the response to prednisolone, but also, on the
other hand, to affect normal leukemic cell viability and
proliferation.118 Collectively, these findings demonstrate
that IKZF1, through modulation of different signaling
pathways and acting directly on glucocorticoid target
genes, alters treatment response, thereby mediating thera-
py resistance in BCP-ALL (Figure 5).
Conclusions and perspectives
From this review it becomes clear that loss of IKZF1
function affects a broad variety of biological pathways
which may all contribute to leukemia development.
Moreover, the  recently established roles for IKZF1 in cell
adhesion, metabolism and glucocorticoid-dependent tar-
get gene regulation seem to be important determinants of
therapy resistance. Preclinical studies are helping with the
identification of  molecular pathways that can be exploit-
ed for targeted therapy of IKZF1-deleted BCP-ALL.  
Over the past decade, a large series of studies conducted
in both childhood and adult ALL have provided clear evi-
dence that IKZF1 alterations predict adverse outcome in
BCP-ALL, both in BCR-ABL1-positive and -negative B-
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Figure 4. Effector pathways downstream of IKZF1 involved in leukemia pathogenesis. Loss of IKZF1 function due to IKZF1 gene deletions and mutations affects
multiple pathways, including pre-B-cell receptor signaling, cell adhesion and proliferation, metabolic pathways and signal transducers and cell surface receptors.
IKZF1 affects the expression of defined key molecules within each of these pathways, as indicated in the boxes. Green boxes define targets that are upregulated
upon loss of IKZF1 function, while red boxes represent repressed targets. SRC: sarcoma proto-oncogene tyrosine kinase; SYK: spleen tyrosine kinase; IGLL1:
immunoglobulin lambda-like polypeptide 1; SLP65: B-cell linker; RHO: RHO family of GTPases ; CTNND1: catenin delta 1/p120 catenin; FAK: focal adhesion kinase;
ITGA5: integrin subunit alpha 5; THY1: thymus cell antigen 1; CDK6: cyclin dependent kinase 6; CDKN1A: cyclin dependent kinase inhibitor 1A; BCL6: B-cell lym-
phoma 6; CDKN2A: cyclin dependent kinase inhibitor 2A; c-MYC: cellular myelocytomatosis oncogene; GLUT1/3/6: glucose transporter 1/3/6; INSR: insuline recep-
tor; HK2: hexokinase 2; HK3: hexokinase 3; AMPK: AMP-activated protein kinase; LKB1: liver kinase B1; G6PD: glucose-6-phosphate dehydrogenase; TXNIP: thiore-
doxin interacting protein; NR3C1: nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor); CNR2: cannabinoid receptor 2; FLT3: FMS related tyro-
sine kinase 3; CD34: hematopoietic progenitor cell antigen;  c-KIT: KIT receptor tyrosine kinase; CD43: sialophorin; IL7R: interleukin 7 receptor.
ALL. However, more recently the role of IKZF1 deletions
as an independent prognostic marker has been
challenged,119 as has the specific contributions of whole
gene versus intragenic dominant-negative IKZF1
deletions.86 One potential explanation for such disparities
may relate to differences in scheduling and dosing of spe-
cific therapeutic agents between different treatment pro-
tocols. It will, therefore, be important to study these pro-
tocol-dependent differences in order to define what is cur-
rently the most efficient treatment for IKZF1-deleted ALL.
Certain adjustments, such as the addition of vincristine-
steroid pulses during maintenance therapy,81 may already
prevent relapses. For the near future, more systematic
screens aimed at determining specific vulnerabilities of
IKZF1-deleted ALL may lead to the identification of tar-
geted therapies that can re-sensitize this high-risk ALL
subgroup to curative treatment.
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Figure 5.  IKZF1 alterations mediate therapy resistance. Overview of IKZF1-affected pathways contributing to tyrosine kinase inhibitor (TKI) resistance and glucocor-
ticoid (GC) resistance. Enhanced cell adhesion due to loss of IKZF1 function has been shown to contribute to both TKI and GC resistance. Deregulation of metabolic
pathways, such as LKB1/AMPK signaling and glucose metabolism, attenuated glucocorticoid receptor (GR) target gene regulation and upregulation of epithelial
membrane protein 1 (EMP1) have been implicated in mediating GC resistance of IKZF1-deleted BCP-ALL. Green boxes indicate activated targets or pathways, while
red boxes define attenuated pathways. Targets within the metabolic pathway can either promote or inhibit GC resistance.  
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